Created at	Source	Raw Value	Validated value
March 29, 2022, 2:30 p.m.	usa	Phase 1 : Characterize the effect of IBIO123 compared to placebo on safety and tolerability;Phase 2: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance	Phase 1 : Characterize the effect of IBIO123 compared to placebo on safety and tolerability;Phase 2: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance